Literature DB >> 11096754

Dystonia.

.   

Abstract

Therapy for most people with dystonia is symptomatic, directed at lessening the intensity of the dystonic contractions. For a small minority of patients (eg, those with dopa-responsive dystonia, Wilson's disease, or psychogenic dystonia), specific therapy directed at one of the many causes of dystonia is available. Before initiating treatment, clinicians need to decide if a patient has a form of dystonia amenable to such therapy. The most sensitive and least costly method to diagnose DRD is a therapeutic trial of levodopa. It is, therefore, recommended to treat all those with dystonia beginning in childhood or adolescence with low-dose levodopa. For patients with generalized or segmental signs who do not respond to levodopa, other oral medications, including anticholinergics, baclofen, and benzodiazepines, may provide mild to moderate relief; these medications are often given in combinations. For those with focal dystonia, most having adult-onset disease, botulinum toxin A injections often effectively control contractions. The injections produce transient weakness and need to be repeated, generally every 3 to 5 months. There is growing renewed interest in surgical treatment. Peripheral denervating procedures may be helpful for patients with torticollis who do not obtain adequate benefit with botulinum toxin A. The central procedures of pallidotomy and pallidal stimulation are under study; their place in the treatment of the many dystonia subtypes (eg, limb vs axial, generalized vs focal, primary vs secondary) still needs to be established. There are very few studies evaluating physical and psychological therapies or the impact of diet or lifestyle in dystonia. Most clinicians consider physical therapy, including massage, a potential adjunct to medical therapy, and psychological support and stress reduction may help individuals cope with this chronic and frequently disabling condition.

Entities:  

Year:  2000        PMID: 11096754     DOI: 10.1007/s11940-000-0009-y

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  18 in total

1.  Selective peripheral denervation in 111 cases of spasmodic torticollis: rationale and results.

Authors:  C M Bertrand; P Molina-Negro
Journal:  Adv Neurol       Date:  1988

2.  Baclofen in the treatment of idiopathic dystonia in children.

Authors:  P E Greene; S Fahn
Journal:  Mov Disord       Date:  1992       Impact factor: 10.338

3.  Oral phenylalanine loading in dopa-responsive dystonia: a possible diagnostic test.

Authors:  K Hyland; J S Fryburg; W G Wilson; E M Bebin; L A Arnold; R S Gunasekera; R D Jacobson; E Rost-Ruffner; J M Trugman
Journal:  Neurology       Date:  1997-05       Impact factor: 9.910

4.  Analysis of open-label trials in torsion dystonia using high dosages of anticholinergics and other drugs.

Authors:  P Greene; H Shale; S Fahn
Journal:  Mov Disord       Date:  1988       Impact factor: 10.338

5.  Neuronal activity in the basal ganglia in patients with generalized dystonia and hemiballismus.

Authors:  J L Vitek; V Chockkan; J Y Zhang; Y Kaneoke; M Evatt; M R DeLong; S Triche; K Mewes; T Hashimoto; R A Bakay
Journal:  Ann Neurol       Date:  1999-07       Impact factor: 10.422

6.  The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein.

Authors:  L J Ozelius; J W Hewett; C E Page; S B Bressman; P L Kramer; C Shalish; D de Leon; M F Brin; D Raymond; D P Corey; S Fahn; N J Risch; A J Buckler; J F Gusella; X O Breakefield
Journal:  Nat Genet       Date:  1997-09       Impact factor: 38.330

7.  Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase I gene.

Authors:  H Ichinose; T Ohye; E Takahashi; N Seki; T Hori; M Segawa; Y Nomura; K Endo; H Tanaka; S Tsuji
Journal:  Nat Genet       Date:  1994-11       Impact factor: 38.330

8.  Spread of symptoms in idiopathic torsion dystonia.

Authors:  P Greene; U J Kang; S Fahn
Journal:  Mov Disord       Date:  1995-03       Impact factor: 10.338

9.  Pallidotomy for generalized dystonia.

Authors:  W G Ondo; J M Desaloms; J Jankovic; R G Grossman
Journal:  Mov Disord       Date:  1998-07       Impact factor: 10.338

10.  Torsion dystonia: a double-blind, prospective trial of high-dosage trihexyphenidyl.

Authors:  R E Burke; S Fahn; C D Marsden
Journal:  Neurology       Date:  1986-02       Impact factor: 9.910

View more
  3 in total

1.  Dopamine receptor and Gα(olf) expression in DYT1 dystonia mouse models during postnatal development.

Authors:  Lin Zhang; Deirdre M McCarthy; Nutan Sharma; Pradeep G Bhide
Journal:  PLoS One       Date:  2015-04-10       Impact factor: 3.240

2.  Long-term quality of life in cervical dystonia after treatment with abobotulinum toxin A: a 2-year prospective study.

Authors:  Subsai Kongsaengdao; Narong Maneeton; Benchalak Maneeton
Journal:  Neuropsychiatr Dis Treat       Date:  2018-04-26       Impact factor: 2.570

3.  KinesioTaping after botulinum toxin type A for cervical dystonia in adult patients.

Authors:  Małgorzata Dec-Ćwiek; Karolina Porębska; Katarzyna Sawczyńska; Marcin Kubala; Magdalena Witkowska; Kinga Zmijewska; Jakub Antczak; Joanna Pera
Journal:  Brain Behav       Date:  2022-03-03       Impact factor: 3.405

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.